Aberdeen Group
RLAY icon

Aberdeen Group’s Relay Therapeutics RLAY Stock Holding History

Aberdeen Group’s Portfolio RLAY Stock Details RLAY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$6.96M Buy
+372,169
New +$5.4M 0.01% 652
2021
Q2 		– Sell
-101,111
Closed -$4.62M – 1030
2021
Q1 		$4.62M Buy
+101,111
New +$4.39M 0.01% 660

Other funds holding RLAY

SIAU
SB Investment Advisers (UK) London, United Kingdom $7.66B AUM 20.12% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return

Aberdeen Group's RLAY Position: Q2 2026 in Review

Aberdeen Group opened a new position in Relay Therapeutics (RLAY) in Q2 2026: 372,169 shares worth $6.96M. The stake represents 0.01% of the portfolio and ranks #652 among its holdings. This is a return to the name: Aberdeen Group previously reported a position in RLAY as recently as Q1 2021.

Aberdeen Group first reported a position in RLAY in Q1 2021 and has held it in 2 quarters since. 260 funds tracked by Wall St. Rank hold RLAY as of Q2 2026.

  • Aberdeen Group held 372,169 shares of Relay Therapeutics worth $6.96M as of Q2 2026.
  • Relay Therapeutics was a new Aberdeen Group position in Q2 2026.
  • Relay Therapeutics made up 0.01% of Aberdeen Group's portfolio in Q2 2026, its #652 holding.
  • Aberdeen Group first reported a position in Relay Therapeutics in Q1 2021 and has held it in 2 quarters since.
  • 260 funds tracked by Wall St. Rank held Relay Therapeutics as of Q2 2026.

Based on Aberdeen Group's 13F filing for Q2 2026, filed 31 Jul 2026.